Keystone Symposium

June 18th, 2019 – Keystone, CO, USA

Learn more

Dieter Willbold will present PRI-002 at the Keystone Symposium “Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2) in Keystone, CO, USA.

News & Events:

Team Assistant (m/w/d)

Team Assistant (m/w/d)

January 28, 2022
Staff Scientist Cellular Assays 

Staff Scientist Cellular Assays 

January 28, 2022
Staff Scientist in vitro ADME

Staff Scientist in vitro ADME

January 28, 2022
TIDES Boston May, 2022

TIDES Boston May, 2022

December 14, 2021
Funding from The Michael J. Fox Foundation

Funding from The Michael J. Fox Foundation

February 24, 2021
Priavoid closes financing round

Priavoid closes financing round

February 12, 2021
Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie

Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie

February 11, 2021
Alzheimer´s Research: Important Milestone for PRI-002

Alzheimer´s Research: Important Milestone for PRI-002

February 4, 2021
Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board

Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board

December 9, 2020
New CEO of Priavoid

New CEO of Priavoid

September 2, 2020
Priavoid Headquarters at LSC Düsseldorf

Priavoid Headquarters at LSC Düsseldorf

March 6, 2020
Seed Investment

Seed Investment

May 6, 2019
Prof. Willbold´s interview with PharmaVentures

Prof. Willbold´s interview with PharmaVentures

January 23, 2018
Clinical trial with PRI-002

Clinical trial with PRI-002

May 31, 2017